Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.67 |
| ▸ | MMP2 | P08253 | 16/20 | 0.67 |
| ▸ | MMP9 | P14780 | 14/20 | 0.67 |
| ▸ | MMP1 | P03956 | 12/20 | 0.67 |
| ▸ | MMP14 | P50281 | 11/20 | 0.67 |
| ▸ | MMP3 | P08254 | 9/20 | 0.67 |
| ▸ | MMP8 | P22894 | 9/20 | 0.67 |
| ▸ | MMP7 | P09237 | 1/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919443 | 0.92 | MMP13 (0.68) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL3624638 | 0.85 | MMP1 (0.69) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919488 | 0.84 | MMP13 (0.75) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL6223029 | 0.84 | PHGDH (0.53) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919519 | 0.81 | MMP13 (0.76) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919424 | 0.80 | MMP13 (0.70) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919664 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919366 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919294 | 0.80 | MMP13 (0.69) | MMP13MMP2MMP9MMP1MMP14 | |
| SCHEMBL5919485 | 0.79 | MMP1 (0.64) | MMP13MMP2MMP9MMP1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | BARTA THOMAS E | 2006-04-20 | — | — | US | disclosed |
| US-6890937-B2 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6750233-B2 | SELECTIVITY | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| EP-1230219-A1 | AROMATIC SULFONS HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. Searle & Co. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | MMP13 1/4885MMP2 4/4885MMP9 2/4885 |
| US-20060084688-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP3 | MMP13 1/4885MMP2 5/4885MMP9 2/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | MMP13 1/4885MMP2 4/4885MMP9 2/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | MMP13 3/4885MMP2 5/4885MMP9 1/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | MMP13 1/4885MMP2 4/4885MMP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.